It was quite a busy and eventful day for the company.

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company ...

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

TPG and Blackstone are teaming up to bid for Bausch + Lomb, with an expected valuation between $13 billion and $14 billion.

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

Bausch + Lomb receives US FDA approval for enVista Envy full range of vision intraocular lens: Vaughan, Ontario Tuesday, October 15, 2024, 17:00 Hrs [IST] Bausch + Lomb Corporatio ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

One Bloomberg estimate projected the sale to value Bausch + Lomb at over $13 billion, making the deal potentially one of the ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...